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Malaria elimination requires tools that interrupt parasite transmission. Here, we 46 
characterized B cell receptor responses among Malian adults vaccinated against the 47 
first domain of the cysteine-rich 230kDa gamete surface protein Pfs2301-3 to neutralize 48 
sexual stage P. falciparum parasites and halt their further spread. We generated nine 49 
Pfs230 human monoclonal antibodies (mAbs). One mAb potently blocked transmission 50 
to mosquitoes in a complement-dependent manner and reacted strongly to gamete 51 
surface while eight mAbs showed only low or no blocking activity. This study provides a 52 
rational basis to improve malaria vaccines and develop therapeutic antibodies for 53 
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MAIN TEXT 67 
Malaria eradication is a global priority and will require innovative strategies that, 68 
in addition to preventing or controlling human infection, might block parasite 69 
transmission through mosquitoes. Sequences of matched heavy and light chain variable 70 
regions from single human B cells have been used to identify antibodies generated in 71 
response to infection or vaccination and inform vaccinology4-7. In this study, we apply 72 
this approach to examine human antibodies elicited in response to a transmission 73 
blocking vaccine (TBV), that used a Pfs230 fragment as antigen. Pfs230 is present on 74 
the surface of P. falciparum gametocytes and gametes and mediates binding of 75 
exflagellating microgametes to red blood cells, thus parasites lacking this protein cannot 76 
bind to red blood cells or further develop into oocysts.1  We collected Pfs230 domain 1 77 
(D1)-specific single memory B cells (Extended Data Fig. 1, Extended Data Fig. 2a) 78 
from eight Malian adults immunized with four doses of Pfs230D1-EPA/Alhydrogel® 79 
vaccine (Clinicaltrials.gov NCT02334462) to identify functional monoclonal antibodies 80 
elicited in response to a TBV. This vaccine aims to neutralize sexual stage P. falciparum 81 
parasites by targeting Pfs230, a 230kDa gamete surface protein comprised of fourteen 82 
6-cysteine (6-Cys) domains1-3. All samples were chosen from subjects presenting high 83 
serum Transmission-Reducing Activity (TRA), measured by the capacity of serum 84 
antibodies from immunized subjects to reduce the number of oocysts that develop in 85 
mosquitoes fed on in vitro cultured P. falciparum gametocytes (Extended Data Table 86 
1). 87 
We obtained 272 VH and 351 VL sequences of B cell receptor (BCR) from 88 
Pfs230D1-specific single memory B cells from the vaccinees via amplification and 89 
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sequencing of the V(D)J region (Extended Data Fig. 3). When analysing V gene usage 90 
of the BCR sequences, 87.5% of the subjects presented Pfs230D1-specific memory B 91 
cells using kappa chains derived from IGKV4-1 (Extended Data Fig. 2e). This light 92 
chain gene has also been identified in sequences of functional human mAbs obtained in 93 
response to other Plasmodium antigens4-6,8. For the heavy chain, IGHV1-69 was the 94 
most commonly expressed gene and detected in 100% (8/8) of vaccinees (Extended 95 
Data Fig. 2f). IGHV1-69 is one of the most polymorphic loci of the IGHV gene cluster9 96 
and is frequently found in broadly neutralizing antibodies generated in response to 97 
influenza haemagluttinin10,11. 98 
Nine pairs of BCR sequences were chosen for expression of fully human 99 
Pfs230D1 IgG1 antibodies by assessing whether the CDR3 sequences were shared 100 
between sorted B cells. This approach identifies identical sequences in multiple B cells 101 
from the same subject, indicating that they have been activated in response to 102 
vaccination. These nine pairs (Fig. 1a) represented distinct heavy and light chain 103 
germline genes with an overabundance of IGHV1-18 (N=6), IGHV1-69 (N=3), and 104 
IGKV4-1 (N=7). The resulting recombinant antibodies bound to Pfs230D1 antigen 105 
(Figure 1d,e, Extended Data Figure 4). Competitive epitope binning of the nine mAbs 106 
suggested they bind three non-overlapping epitopes in Pfs230D1 (Fig. 1b). LMIV230-01 107 
forms a distinct group (Group 1) and has potent neutralizing activity (Fig. 1b, c). The 108 
remaining mAbs do not compete with LMIV230-01 and may form two additional epitope 109 
groups. Group 2 and 3 mAbs possess low or no neutralizing activity (Fig. 1c). We 110 
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therefore focused most of our subsequent analyses on LMIV230-01 and to a lesser 111 
extent on LMIV230-02, which demonstrated low functional activity. 112 
LMIV230-01 and 02 bound to Pfs230D1 recombinant protein (Fig. 1d) with 113 
strong and similar binding affinities (Fig. 1e, Extended Data Fig. 4, Extended Data 114 
Table 2). We confirmed the two mAbs bind distinct epitopes using competition ELISA 115 
(Extended data Figure 5d) consistent with the epitope binning results (Fig. 1b). 116 
Despite their shared use of IGHV1-69, LMIV230-01 and LMIV230-02 displayed 117 
numerous differences in their heavy chain CDRs, consistent with their recognition of 118 
distinct epitopes (Extended Data Figure 12).  119 
Although presenting similar affinity to Pfs230D1, the mAbs differed in their 120 
functional activity as measured by SMFA. LMIV230-01 ablated P. falciparum oocyst 121 
burden in mosquitoes in a dose-dependent manner with 91.7% neutralization (TRA) at 122 
1000 µg/mL (Fig. 1f). Importantly, 80.3% neutralization was retained at 60 µg/mL. On 123 
the other hand, LMIV230-02 reduced oocyst burden by only 58.7% at the maximum 124 
concentration of 1000 µg/mL and activity was lost at 250 µg/mL. As previously reported, 125 
TRA values higher than 80% are highly reproducible across independent 126 
experiments12,13.Combining the two antibodies did not increase their overall activity: 127 
TRA values were not statistically different when 500µg of LMIV230-02 was combined 128 
with 10µg of LMIV230-01 (TRA= 58.7%) versus 10µg of LMIV230-01 alone (TRA= 129 
52.5%) in mosquito feeding assays (Extended Data Figure 5e).  130 
To understand the differences in functional activity of the two mAbs, we 131 
assessed binding to the native protein. Both mAbs reacted to the protein extract of 132 
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parasites and were sensitive to reduction of the two disulfide-bonds, suggesting the 133 
presence of conformational epitopes (Fig. 1g, Extended Data Fig. 5c). Interestingly, 134 
LMIV230-01 strongly labelled the surface of live P. falciparum gametes purified 2 hours 135 
post-exflagellation, while LMIV230-02 did not (Fig.  1h).  This suggests that the 136 
LMIV230-02 epitope is not completely accessible on the surface-displayed native 137 
protein, possibly due to structural limitations imposed by the multi-domain protein 138 
Pfs230, as has been seen for other proteins14,15 including another 6-Cys TBV 139 
candidate16.  140 
 141 
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Fig. 1| Human recombinant mAbs were generated from Pfs230D1-specific single memory B cells 143 
of Malian adults vaccinated with the Pfs230D1-EPA/Alhydrogel® TBV. a, VH and VL genes 144 
corresponding to each mAb. LMIV230-01 and LMIV230-02 sequences originate from the IGHV1-69 heavy 145 
chain gene but utilize different kappa chain genes. Complete V gene usage determined in Pfs230-specific 146 
memory B cells is described in Extended Data Figures 2e,f. b, Epitope binning of human anti-147 
Pfs230D1scFvs. The primary binding scFv is listed on the left and the competing scFv are listed on the 148 
top. Reported scores are a percentage of total binding of that antibody in the absence of a competitor 149 
scFv. Values greater that 50% display low amounts of competition, while values lower than 50% exhibit 150 
greater competition. Any experiment with >100% binding was given a score of 100, while negative values 151 
were given a score of 0. Potential epitope bins are grouped and labelled above the table. c, Functional 152 
activity of each mAb, assessed by Standard Membrane Feeding Assay (SMFA) and measured as the % 153 
reduction (versus control mAb) in the number of P. falciparum NF54 oocysts in midguts of Anopheles 154 
mosquitoes (“TRA”). d, LMIV230-01 and LMIV230-02 mAbs bound similarly to Pfs230D1 and  e, show 155 
high affinity to recombinant Pfs230D1 (Extended Data Fig. 4, Extended Data Table 2) f, LMIV230-01 156 
reduces P. falciparum NF54 oocyst numbers by 91.7% at 1000 µg/mL, 86.7% at 500 µg/mL, 84.4% at 157 
250 µg/mL and 80.3% at 60 µg/mL, while LMIV230-02 displays only modest activity with 58.7% reduction 158 
at the maximum concentration of 1000 µg/mL, in SMFA.  Data from eleven independent SMFA and each 159 
concentration was evaluated in at least three biological replicates for each mAb. N ≥ 20 mosquitos per 160 
assay. Average oocyst numbers in the control mosquitoes (fed with mouse IgG1 mAb targeting P. yoelii 161 
P140 protein) for each experiment were: exp. 1 = 29.73; exp.2= 7.18; exp. 3= 57.86; exp. 4= 36.41; exp. 162 
5= 51.71, exp. 6= 4.55; exp. 7= 62.35; exp. 8= 20.50, exp.9= 8.71, exp 10= 18.05, exp. 11= 5.86. 163 
Negative oocyst reduction values were set to zero. Human isotype IgG1 and US human serum pool were 164 
used as additional negative controls (Extended Data Fig. 5b). Values are shown as mean ± s.e.m. g, 165 
LMIV230-01 and LMIV230-02 bind to non-reduced (NR) protein extract of P. falciparum NF54 gametes 166 
purified on Nycodenz after 2 hours in exflagellation medium. h, LMIV230-01 strongly binds to gametes at 167 
7.5µg/mL while LMIV230-02 does not bind at 7.5µg/mL. or 30µg/mL. Both mAbs were labelled with Alexa 168 
Fluor 488. Scale bars: 5µM. 169 
 170 
LMIV230-01 bound strongly to fixed parasites in numerous developmental stages 171 
including gametocytes, exflagellation centers, microgametes, macrogametes and round 172 
forms (zygotes) collected 4 hours after mosquito feeding. As expected, the mAb did not 173 
bind to the post-fertilization stage ookinetes, obtained 24 hours after the mosquito 174 
bloodmeal (Fig. 2a).  175 
Pfs230 antibody activity depends on complement fixation to lyse P. falciparum17. 176 
To test whether the activity of LMIV230-01 was dependent on activation of the 177 
complement system, we incubated parasites with LMIV230-01 in the presence of intact 178 
or heat-inactivated sera from US donors then assessed lysis of gametes (Fig. 2b) as 179 
well as transmission of parasites fed to mosquitoes after treatment using the same 180 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted September 26, 2020. ; https://doi.org/10.1101/2020.09.25.313478doi: bioRxiv preprint 
9 
 
conditions (Fig. 2c). Functional activity of LMIV230-01 to lyse gametes and block oocyst 181 
formation in mosquitoes was substantially reduced in the heat-inactivated sera (Figs. 182 
2b and 2c), demonstrating complement-dependency. Activation of complement leads to 183 
the formation of the membrane attack complex (MAC), an assembly of the complement 184 
molecules C5b, C6, C7, C8, and C918,19 on the parasite surface. Using an antibody that 185 
recognizes assembled MAC, we demonstrated complement fixation on the surface of 186 
live P. falciparum gametes that were incubated with LMIV230-01 in the presence of 187 
intact but not heat-inactivated serum (Fig. 2d and Extended Data Fig. 7).   188 
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Fig. 2| LMIV230-01 binds to multiple parasite stages and its activity is complement-dependent. a, 190 
LMIV230-01 strongly binds to permeabilized gametocytes, gametes and zygotes and does not bind to 191 
ookinetes. Parasites were fixed and permeabilized, and 7.5 µg/mL of antibody was used to stain the 192 
different parasite stages. Scale bars: 5µM. b, In vitro parasite lysis by LMIV230-01 is complement-193 
dependent. Samples were tested in two independent assays, using two different parasite cultures c, 194 
Functional activity of LMIV230-01 is also complement-dependent in vivo (SMFA with mosquitoes). Data 195 
from three independent SMFA assays. N ≥ 20 mosquitos per assay. Oocyst averages in the control 196 
mosquitoes (fed with IgG1 targeting P. yoelli P140) for each of the experiments were: exp. 1= 4.55; exp. 197 
2= 20.50, exp. 3=5.86. Data obtained from mosquitoes fed with LMIV230-01 at 1000 µg/mL with intact 198 
sera were also used to generate figure 1f. Values are shown as mean ± s.e.m. One-Way ANOVA and  199 
Turkey’s multiple comparisons test were used to compare the different groups d, Live imaging of P. 200 
falciparum NF54 female gametes incubated with LMIV230-01 in the presence of intact serum from a 201 
healthy donor revealed surface-deposited MAC (membrane attack complex) using anti-C5b-9+C5b-8 202 
antibody (magenta color). MAC deposition was not detected in the presence of heat-inactivated (HI) 203 
serum. Scale bars: 5µM. 204 
 205 
To assess whether LMIV230-01 would also bind to other P. falciparum strains, 206 
we prepared gametocytes from a culture-adapted Malian isolate 20 and from St. Lucia 207 
strain (originally from El Salvador) 21. LMIV230-01 labelled in vitro-induced gametes 208 
from both strains (Fig. 3a and b). Induction of gamete stage from the newly 209 
characterized Malian isolate was confirmed using a murine anti-Pfs48/45 mAb (Fig. 3c). 210 
LMIV230-01 fixed complement on the gamete surface of both strains, confirming that 211 
the antibody is functional against heterologous parasites (Figs. 3d and e).  212 
To assess the abundance of antibodies that share paratope specificity with 213 
LMIV230-01, we developed an ELISA assay to demonstrate the competition between 214 
post-vaccination sera (tested at a 1:2500 dilution) and LMIV230-01 for binding the 215 
vaccine antigen (Figure 3f). Among subjects who received the vaccine, levels of 216 
competing antibody ranged from ~10-70% displacement of Pfs230D1 binding to 217 
LMIV230-01, with a normal distribution confirmed by Shapiro-Wilk test (p= 0.52) (Figure 218 
3g). Levels of competition strongly correlated with total Pfs230D1 IgG titers in sera 219 
(Spearman’s rho= 0.604, p<0.0001) (Figure 3h). Increasing levels of competing 220 
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antibody also corresponded to serum functional activity measured by SMFA. Because 221 
serum TRA levels of vaccines were high with minimal variability ranging from 95-100% 222 
(Extended Data Figure 14), our primary correlation analysis used TBA (Transmission 223 
Blocking Activity) which indicates the % reduction in the proportion of infected 224 
mosquitoes, a high bar for TBV activity generally seen only when TRA is very high. 225 
Correlation analyses showed that % serum competition was related to TBA 226 
(Spearman’s rho= 0.324, p= 0.05) (Figure 3i), suggesting that antibodies that compete 227 
for the LMIV230-01 epitope play an important role in serum functional activity. This 228 
result, however, does not exclude the possible role of antibodies that do not compete 229 
with LMIV230-01 in mediating vaccine activity, and notably some sera with high TBA 230 
demonstrated low levels of LMIV230-01 competing antibodies. 231 
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Figure 3| LMIV230-01 binds to heterologous P. falciparum strains and antisera from Pfs230D1 233 
vaccinees vary widely in levels of antibody that compete with LMIV230-01 for binding. a, LMIV230-234 
01 bound to gametes of St. Lucia parasite strain and b, of an isolate obtained from a Malian adult and 235 
adapted to culture. c, Murine anti-48/45 mAb confirms formation of gametes by Malian isolate and its 236 
signal colocalizes with LMIV230-01. “Merged” refers to combination of green and red channels. d, 237 
Membrane attack complex forms on gametes of St. Lucia strain and e, of a Malian isolate incubated with 238 
LMIV230-01 in the presence of intact but not heat-inactivated serum. Scale bars for all images in this 239 
panel: 5µM. f, Cartoon schematizing LMIV230-01 competition ELISA assay. g, Distribution of serum 240 
antibody levels that compete with LMIV230-01 for binding to Pfs230D1 in 36 subjects who received 241 
Pfs230D1-EPA vaccine. Values displayed represent mean from three independent experiments. h, 242 
Relationship of LMIV230-01-competing antibody levels to total Pfs230D1 antibody titers, or i, to serum 243 
functional activity (TBA, transmission blocking activity) measured by SMFA. 244 
 245 
Altogether, our data confirm that vaccination with TBV can elicit strong 246 
neutralizing antibodies, capable of binding to gametocytes, gametes, and zygotes, and 247 
of impairing fertilization in the mosquito. Due to its complex domains and repeating 248 
motifs with numerous disulfide bonds, expression of full length Pfs230 has been 249 
difficult22,23. Preclinical studies of Pfs230 fragments have shown that immunization with 250 
recombinant domain 1 of Pfs230 (Pfs230D1), but not other domains, induces strong 251 
functional TRA in SMFA3,22,24.  252 
Our data support further development of TBV strategies to induce potent 253 
antibody responses against mosquito sexual stage parasites. 254 
255 
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EXTENDED DATA - FIGURES 304 
 305 
 306 
Extended Data Fig. 1| Experimental pipeline. Pfs230D1-specific single B cells were sorted from PBMCs 307 
of eight Malian adults who had been immunized with four doses of 40µg of Pfs230D1-EPA/Alhydrogel®. 308 
After extraction of single B cells, a 500 bp fragment of the BCR variable regions of VH/VL were amplified 309 
and sequenced. Matched VH/VL pairs that were identified in more than one B cell were preferentially 310 
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Extended Data Fig. 2| Pfs230D1-specific mAbs belong to the same heavy chain germline subgroup 317 
but differ for kappa chain. a, Sorted memory B cells were gated as live, single cells, excluded for CD3, 318 
CD14 and CD56, and gated on CD19+, CD20+, CD27+ cells. Then, a tetramer approach was used to 319 
select antigen-specific cells and reduce nonspecific binding. Cells binding to the decoy tetramer (BSA) 320 
were excluded and only those binding to Pfs230D1 were selected for sorting. b, Serum from each subject 321 
was used to measured antibody titers against Pfs230D1 and functional activity to reduce oocyst burden in 322 
Standard Membrane Feeding Assays (SMFA). TRA= Transmission Reducing Activity measured as the 323 
reduction in average oocyst count; TBA= Transmission Blocking Activity measured as the reduction in the 324 
proportion of infected mosquitoes. c, Proportion of memory B cells for each subject that are Pfs230D1-325 
specific.  d, Complementarity-determining regions (CDRs) of each sequence selected for mAb 326 
expression. e, IGKV4-1 germline (gene sequence in LMIV230-02) was the most frequent for the kappa 327 
chain genes. IGKV1-5 germline (gene sequence in LMIV230-01) was found in only three subjects f, 328 
Sequences related to germline 1-69 of the IGHV gene were the most frequently elicited in response to the 329 
vaccination. 330 
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Extended Data Fig. 3| Amplification of V(D)J region. 500 bp fragment amplified from cDNA of sorted 331 
Pfs230D1-specific single B cell. This fragment was obtained using primers targeting the V(D)J region 332 
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Extended Data Fig.5| Additional binding and functional characterization of LMIV230-01 and -02. a, 340 
Both mAbs failed to bind to the ookinete protein Pfs25. b, Additional controls for the Standard Membrane 341 
Feeding Assay (SMFA). Human IgG1 isotype control was expressed using the same conditions as 342 
LMIV230-01 and -02 and was used in this assay at 1000µg/mL. Sixty microliters of undiluted human 343 
pooled serum obtained from US healthy donors were used as additional control. Values are shown as 344 
mean ± s.e.m. c, Full depiction of the Western blot gel displayed in Fig. 1g .d, The two mAbs do not 345 
compete for the same epitope in the recombinant Pfs230D1 protein, since unlabelled LMIV230-01 blocks 346 
binding of LMIV-230-01-HRP to immobilized Pfs230D1 but LMIV230-02 does not. e, Combination of 347 
LMIV230-01 and LMIV230-02 did not increase functional activity over LMIV230-01 alone.  Control 348 
mosquitoes were fed with mouse IgG1 mAb targeting P. yoelii P140 protein, or with non-immune human 349 
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Extended Data Fig.7| Pfs230 mAbs activity is complement-dependent and LMIV230-01 competing 363 
antibodies are acquired at varying levels by vaccinees. a, Activity of LMIV230-01 and LMIV230-02 is 364 
complement-dependent in the vitro lysis assay and b, in the vivo mosquito feeding assay. c, Membrane 365 
attack complexes (MAC) on parasites were detected using an Alexa 488-labeled antibody that recognizes 366 
the assembled MAC complex (anti C5b-9+ C5b-8). Gametes incubated with LMIV230-01 and intact 367 
serum produced MAC-positive parasites. Heat-inactivating serum to degrade the heat-labile components 368 
of the complement pathway eliminated deposition of MAC on gametes. MAC-positive P. falciparum strain 369 
NF54 gametes were enumerated in a large, tiled confocal image and normalized to the number of 370 









(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 

























Spearman's rho= 0.309, p= 0.06
 385 
Extended Data Fig. 14| Correlation between levels of LMIV230-01 competing antibodies and 386 
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TRA (%) TBA (%) 
1 944 99.9 96 
2 1581 99.3 73.9 
3 2115 100 100 
4 1382 99.6 79.2 
5 2100 100 100 
6 5277 100 100 
7 800 99.9 95.8 
8 774 95.1 20.8 
 401 
Extended Data Table 1- Antibody titers and functional activity of sera from the eight subjects whose 402 
sequences were analyzed in this study. TRA= Transmission-reducing activity. TBA=Transmission 403 




(x 10-10  SEM M) 
ka 
(x 105  SEM 1/Ms) 
kdis 
(x 10-4  SEM 1/s) 
N 
LMIV230-01  
Biological Replicate 1 
 
1.58  0.77 
 
1.71  0.06 
 
0.28  0.15 
 
   3 
Biological Replicate 2 2.06  0.99 1.80  0.04 0.37  0.18 3 
 
LMIV230-02  
Biological Replicate 1 
 
6.36  0.24 
 
7.67  0.21 
 
4.87  0.06 
 
3 
Biological Replicate 2 4.27  0.22 6.37  0.13 2.71  0.10 3 
 407 
Extended Data Table 2- Binding of mAbs LMIV230-01 and LMIV230-02 to Pfs230D1 using Biolayer 408 
Interferometry.  Binding data for each mAb was fitted using a 1:1 binding model. The averages for two 409 
biological replicates, composed of three technical replicates each, are shown for both mAbs.  410 
 411 
 412 
[EXT. DATA TABLES 3-7 WILL BE AVAILABLE IN THE PUBLISHED VERSION] 413 
 414 
415 
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